Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.710
+0.080 (4.91%)
At close: Oct 29, 2024, 4:00 PM
1.700
-0.010 (-0.58%)
After-hours: Oct 29, 2024, 7:56 PM EDT

Akebia Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 5.75, with a low estimate of 4.00 and a high estimate of 7.50. The average target predicts an increase of 236.26% from the current stock price of 1.71.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $4.00 $5.75 $7.50 $7.50
Change +133.92% +236.26% +338.60% +338.60%

Analyst Ratings

The average analyst rating for AKBA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating May '24Jun '24Jul '24Aug '24Sep '24Oct '24
Strong Buy 222222
Buy 111000
Hold 000000
Sell 000000
Strong Sell 000000
Total 333222

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$7.5
Strong Buy Reiterates $7.5 +338.60% Oct 23, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$7.5
Strong Buy Reiterates $7.5 +338.60% Oct 10, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$7.5
Strong Buy Reiterates $7.5 +338.60% Oct 8, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$7.5
Strong Buy Reiterates $7.5 +338.60% Sep 6, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$6$7.5
Strong Buy Maintains $6$7.5 +338.60% Aug 12, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
175.44M
from 194.62M
Decreased by -9.86%
Revenue Next Year
181.10M
from 175.44M
Increased by 3.23%
EPS This Year
-0.25
from -0.28
EPS Next Year
-0.26
from -0.25
Fiscal Year FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2019 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
335.00M294.64M211.65M292.48M194.62M175.44M181.10M251.37M
Revenue Growth
61.26%-12.05%-28.17%38.19%-33.46%-9.86%3.23%38.80%
EPS
-2.36-2.78-1.70-0.52-0.28-0.25-0.260.15
EPS Growth
--------
Forward PE
-------11.56
No. Analysts -----554
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20242025202620272028
High 186.4M 244.1M 261.2M
Avg 175.4M 181.1M 251.4M
Low 158.7M 126.7M 239.2M

Revenue Growth

Revenue Growth 20242025202620272028
High
-4.2%
39.2%
44.2%
Avg
-9.9%
3.2%
38.8%
Low
-18.5%
-27.8%
32.1%

EPS Forecast

EPS 20242025202620272028
High -0.17 0.09 0.44
Avg -0.25 -0.26 0.15
Low -0.32 -0.46 -0.13

EPS Growth

EPS Growth 20242025202620272028
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.